zileuton has been researched along with sb 210313 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, JL; Badger, AM; Boehm, JC; Bradbeer, J; Breton, JJ; Chabot-Fletcher, MC; Gallagher, TF; Garigipati, RS; Griswold, DE; Hillegass, LM; Laydon, JT; Lee, JC; Sheldrake, PL; Smietana, JM; Sorenson, ME | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
2 other study(ies) available for zileuton and sb 210313
| Article | Year |
|---|---|
1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Arthritis; Bone Density; Cyclooxygenase Inhibitors; Cytokines; Imidazoles; Lipoxygenase Inhibitors; Mice; Mice, Inbred BALB C; Molecular Structure; Morpholines; Prostaglandin-Endoperoxide Synthases; Protein Kinases; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 1996 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |